{
    "nct_id": "NCT05206357",
    "official_title": "A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients With Relapsed/Refractory Aggressive Mature B-cell Neoplasms",
    "inclusion_criteria": "* Participants >= 1 and < 18 years old at time of primary diagnosis with Burkitt's or Burkitt-like lymphoma/leukemia, diffuse large B-cell lymphoma (DLBCL), or other aggressive mature (CD20+) B-cell lymphomas. Participants up to 25 years of age with Burkitt's or Burkitt-like lymphoma/leukemia are also eligible.\n* Disease pathologically confirmed (tumor tissue) by local testing.\n* Relapsed or primary refractory disease meeting any of the following criteria:\n\n  * Progressive disease at any time during second-line chemoimmunotherapy (CIT).\n  * Best response of stable disease (SD) after a minimum of 2 cycles of second-line CIT.\n  * Best response of partial response (PR) after a minimum of 3 cycles of second-line CIT.\n  * Complete Response (CR) after a minimum of 3 cycles of second-line CIT therapy but unfit or ineligible for consolidation with cell therapy.\n  * Not in CR and unable to initiate or tolerate (i.e., must discontinue) second-line CIT.\n  * Have received cell therapy (allogeneic or autologous transplant or chimeric antigen receptor T-cell (CAR-T) therapy) as consolidation but have not obtained or maintained a CR.\n* Recovery from toxic effects of prior chemoimmunotherapy.\n* Performance status by Lansky (< 16 years old at evaluation) or Karnofsky (>= 16 years old at evaluation) score >= 50 or Eastern Cooperative Oncology Group (ECOG) score <= 2 .\n* Adequate bone marrow, hepatic, and renal function.\nHealthy volunteers allowed\nMust have minimum age of 1 Year\nMust have maximum age of 25 Years",
    "exclusion_criteria": "* Known central nervous system (CNS) involvement by lymphoma at screening as confirmed by screening magnetic resonance imaging (MRI)/computed tomography (CT)/positron emission tomography (PET) brain scans (participants with evidence of CNS disease only in the cerebrospinal fluid (CSF) will be eligible).\n* Other malignancy requiring therapy.\n* Currently receiving anti-cancer therapy, including chemotherapy (excluding intrathecal therapy), radiotherapy, small molecules, monoclonal antibodies, cell therapy, or other investigational agents.",
    "miscellaneous_criteria": ""
}